Paper32190816
Back to the Future-Moving Forward for Testicular Cancer Survivors.
Nichols CR and 4 others. JNCI Cancer Spectr, 2020. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Back to the Future-Moving Forward for Testicular Cancer Survivors. Papers, record 32190816. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32190816
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References7
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30875280 | Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30875280 | PubMed |
| 2 | 32190815 | Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. | JNCI Cancer Spectr | 2020 | https://conductscience.org/library/papers/32190815 | PubMed |
| 3 | 29617189 | Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29617189 | PubMed |
| 4 | 30802156 | Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30802156 | PubMed |
| 5 | 20585105 | Testicular cancer survivorship: research strategies and recommendations. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20585105 | PubMed |
| 6 | 27185842 | Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27185842 | PubMed |
| 7 | 23592702 | Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23592702 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 34281219 | The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something? | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34281219 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HSPB1 | 3315 | PubTator's text mining | https://conductscience.org/library/genes/3315 | NCBI Gene |
| MIR371A | 442916 | PubTator's text mining | https://conductscience.org/library/genes/442916 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32190816
GET https://conductscience.org/api/papers/v1/32190816/authors